We are live on ! Find out more
VPC

Vestal Point Capital Portfolio holdings

AUM $3.58B
1-Year Est. Return 189.12%
This Fund
S&P 500
This Quarter Est. Return
-16.95%
1 Year Est. Return
+189.12%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.4B
AUM Growth
-$286M
Cap. Flow
-$9.42M
Cap. Flow %
-0.67%
Top 10 Hldgs %
51.45%
Holding
86
New
13
Increased
27
Reduced
13
Closed
23

Top Buys

Rank Stock Value
1
ACLX
Arcellx
ACLX
+$130M
2
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$56M
3
SRRK icon
Scholar Rock
SRRK
+$50M
4
VERA icon
Vera Therapeutics
VERA
+$45.8M
5
NUVL
Nuvalent
NUVL
+$37.1M

Top Sells

Rank Stock Value
1
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$120M
2
MRK icon
Merck
MRK
+$79.6M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$56.5M
4
ASND icon
Ascendis Pharma A/S
ASND
+$52.8M
5
SLNO
Soleno Therapeutics
SLNO
+$47.6M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LQDA icon
26
Liquidia Corp
LQDA
$7.92B
$18.1M 1.29%
1,227,403
-532,597
-30% -$7.77M
COGT icon
27
Cogent Biosciences
COGT
$7.27B
$18M 1.28%
+3,000,000
New +$23.5M
ESTA icon
28
Establishment Labs
ESTA
$2.32B
$17.7M 1.26%
433,193
+133,193
+44% +$4.97M
VRNA
29
DELISTED
Verona Pharma
VRNA
$17M 1.21%
267,627
-227,373
-46% -$13.6M
PRGO icon
30
Perrigo
PRGO
$1.79B
$16.5M 1.18%
587,649
+212,649
+57% +$5.51M
GEHC icon
31
GE HealthCare
GEHC
$32.3B
$16.5M 1.18%
+204,130
New +$17.5M
NYXH
32
Nyxoah
NYXH
$142M
$16.2M 1.16%
2,318,954
-605,262
-21% -$6.16M
GMED icon
33
Globus Medical
GMED
$11.1B
$14.6M 1.05%
200,000
-125,000
-38% -$10.3M
NRIX icon
34
Nurix Therapeutics
NRIX
$2.63B
$13.4M 0.95%
1,125,552
+640,552
+132% +$10.7M
SRPT icon
35
Sarepta Therapeutics
SRPT
$1.77B
$12.8M 0.91%
200,000
-50,000
-20% -$5.26M
BRKR icon
36
Bruker
BRKR
$8.07B
$12.5M 0.89%
+300,000
New +$15.6M
CDTX
37
DELISTED
Cidara Therapeutics
CDTX
$10.9M 0.78%
+504,542
New +$11.2M
BDTX icon
38
Black Diamond Therapeutics
BDTX
$110M
$8.68M 0.62%
5,600,000
– –
MLTX icon
39
MoonLake Immunotherapeutics
MLTX
$1.55B
$7.81M 0.56%
+200,000
New +$8.62M
SLDB icon
40
Solid Biosciences
SLDB
$833M
$6.49M 0.46%
1,753,558
-1,096,442
-38% -$4.69M
IMVT icon
41
Immunovant
IMVT
$8.13B
$5.98M 0.43%
350,000
+305,000
+678% +$6.38M
ZYME icon
42
Zymeworks
ZYME
$1.75B
$5.96M 0.43%
500,000
+315,000
+170% +$4.3M
APLT
43
DELISTED
Applied Therapeutics
APLT
$5.62M 0.4%
11,500,000
– –
ITOS
44
DELISTED
iTeos Therapeutics
ITOS
$5.37M 0.38%
900,000
– –
LKFT
45
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.76B
$5.02M 0.36%
200,000
+20,000
+11% +$505K
VYGR icon
46
Voyager Therapeutics
VYGR
$196M
$4.22M 0.3%
1,249,418
+19,418
+2% +$90.7K
LXEO icon
47
Lexeo Therapeutics
LXEO
$362M
$3.94M 0.28%
1,136,249
-63,751
-5% -$282K
KNSA icon
48
Kiniksa Pharmaceuticals
KNSA
$5.92B
$3.77M 0.27%
+169,864
New +$3.5M
CLDX icon
49
Celldex Therapeutics
CLDX
$3.26B
$3.61M 0.26%
198,646
-106,354
-35% -$2.38M
OKUR
50
OnKure Therapeutics
OKUR
$168M
$2.73M 0.2%
635,000
– –
1
2
3 4

Similar funds

WWA
WCG Wealth Advisors Las Vegas, Nevada $3.57B AUM 18.63% 1-Year Est. Return
BPS
BNDES Participacoes SA Rio De Janeiro, Brazil $3.58B AUM
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
U
Uber San Francisco, California $3.6B AUM 19.81% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $3.54B AUM 19.14% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return
ACM
Advent Capital Management New York $3.63B AUM 0.29% 1-Year Est. Return

Vestal Point Capital's Q1 2025 Portfolio in Review

As of Q1 2025, Vestal Point Capital held 86 positions worth $1.4B, down 17% from $1.69B the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Vestal Point Capital's Q1 2025 filing shows 13 new, 27 increased, 13 reduced and 23 closed positions. Its largest new stake was Crinetics Pharmaceuticals: 1,500,000 shares worth $50.3M. The largest sale was Jazz Pharmaceuticals, an estimated $120M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Vestal Point Capital's largest Q1 2025 buy was Crinetics Pharmaceuticals: 1,500,000 shares worth $50.3M.
  • Vestal Point Capital added most to Arcellx in Q1 2025, an estimated $130M increase.
  • Vestal Point Capital's biggest Q1 2025 reduction was Ascendis Pharma A/S, cutting an estimated $52.8M.
  • Vestal Point Capital fully exited Jazz Pharmaceuticals in Q1 2025, selling an estimated $120M.
  • Vestal Point Capital's ten largest holdings make up 51% of its $1.4B portfolio in Q1 2025.
  • Vestal Point Capital opened 13 new positions and closed 23 in Q1 2025.
  • Vestal Point Capital's portfolio value fell 17% quarter-over-quarter to $1.4B.

Based on Vestal Point Capital's 13F filing for Q1 2025, filed 15 May 2025.